APA (7th ed.) Citation

Raghu, G., van den Blink, B., Hamblin, M. J., Brown, A. W., Golden, J. A., Ho, L. A., . . . Richeldi, L. (2019). Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: An open-label extension study. The lancet. Respiratory medicine, 7(8), . https://doi.org/10.1016/S2213-2600(19)30172-9

Chicago Style (17th ed.) Citation

Raghu, Ganesh, et al. "Long-term Treatment with Recombinant Human Pentraxin 2 Protein in Patients with Idiopathic Pulmonary Fibrosis: An Open-label Extension Study." The Lancet. Respiratory Medicine 7, no. 8 (2019). https://doi.org/10.1016/S2213-2600(19)30172-9.

MLA (9th ed.) Citation

Raghu, Ganesh, et al. "Long-term Treatment with Recombinant Human Pentraxin 2 Protein in Patients with Idiopathic Pulmonary Fibrosis: An Open-label Extension Study." The Lancet. Respiratory Medicine, vol. 7, no. 8, 2019, https://doi.org/10.1016/S2213-2600(19)30172-9.